Compass pathways stock forecast.

For Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...CMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: CMPS's weekly volatility (9%) has been stable over the past year.We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. …

CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share).

COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.WebData Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...

For Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... What this means: InvestorsObserver gives Compass Pathways Plc ADR (CMPS) an overall rank of 34, which is below average. Compass Pathways Plc ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.Aug 16, 2023 · The private placement is being conducted in accordance with applicable rules of the Nasdaq Stock Market LLC (“Nasdaq”) and was priced to satisfy the “Minimum Price” requirement (as defined ... COMPASS Pathways ’s (CMPS) stock price is $6.1 and COMPASS Pathways ’s (CMPS) 100-day simple moving average is 7.59, creating a Sell signal. COMPASS Pathways ’s ( CMPS ) stock price is $6.1 and COMPASS Pathways ’s ( CMPS ) 200-day simple moving average is 8.13 , creating a Sell signal.

A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

TipRanks

Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.WebThe current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...Step 3: Place your order and invest in CMPS. Place your order by following these simple steps: Step 1: Locate Compass Pathways by using its ticker symbol CMPS; Step 2: Decide on the order type. The two most common options available to you will be a market order, filled immediately, or a limit order, fulfilled at your predetermined price point ...

Compare with up to 5 Stocks. On Monday 11/06/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.05 on NAS. Compared to the opening price on Monday 11/06/2023 on NAS of ...WebCompass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range. 11.48.Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis.CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...WebCOMPASS Pathways (CMPS) Stock Forecast & Price Prediction. Estimation of the future price movement of COMPASS Pathways stock, based on various factors such as …COMPASS Pathways ’s (CMPS) stock price is $6.1 and COMPASS Pathways ’s (CMPS) 100-day simple moving average is 7.59, creating a Sell signal. COMPASS Pathways ’s ( CMPS ) stock price is $6.1 and COMPASS Pathways ’s ( CMPS ) 200-day simple moving average is 8.13 , creating a Sell signal.

And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.

-1.40 Crude Oil (-0.32%) Gold COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 5.93 -0.05 (-0.84%) At close: 04:00PM EST 6.03 +0.10 (+1.69%) After... For Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...Low. $35.00. Average. $71.83. Current Price. $60.31. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Some... Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst...The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...Compass Pathways (NASDAQ: CMPS) is owned by 35.95% institutional shareholders, 57.27% Compass Pathways insiders, and 6.79% retail investors. Ekaterina Malievskaia is the largest individual Compass Pathways shareholder, owning 12.82M shares representing 20.71% of the company. Ekaterina Malievskaia's Compass Pathways shares are …

Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...

9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.

See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Dec 1, 2023 · See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Compass Pathways PLC Follow Share $5.83 After Hours: $6.12 (4.97%) +0.29 Closed: Nov 21, 6:09:39 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Mind Medicine (MindMed) Inc $2.68 MNMD2.55%... Get a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Some... Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst...COMPASS Pathways (CMPS) Insider Trading Activity 2023. S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) 13 crew members missing after a cargo ship …Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? (NYSE: COMP) forecast ROE is N/A, which is considered weak.WebCOMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... Research COMPASS Pathways' (Nasdaq:CMPS) stock key valuation metrics while comparing it with its industry peers & market side by side. Research COMPASS ... The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual …See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The current Compass Pathways PLC [ CMPS] share price is $6.45. The Score for CMPS is 52, which is 4% above its historic median score of 50, and infers lower risk than normal. CMPS is currently trading in the 50-60% percentile range relative to its …WebInstagram:https://instagram. high risk high reward investmentsnyse crkworkday salesforcefvd etf 17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics. bpt stock dividendiso coin 17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 … fidelity small cap growth index fund 49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 …UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ...